Pazopanib for Metastatic Alveolar Soft Part Sarcoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

November 30, 2017

Conditions
Metastatic Alveolar Soft Part Sarcoma
Interventions
DRUG

Pazopanib

Pazopanib 800mg qd daily for 4 weeks = 1 cycle

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

Asan Medical Center

OTHER

collaborator

Samsung Medical Center

OTHER

collaborator

Severance Hospital

OTHER

lead

Seoul National University Hospital

OTHER

NCT02113826 - Pazopanib for Metastatic Alveolar Soft Part Sarcoma | Biotech Hunter | Biotech Hunter